Enterococcus News and Research

RSS

Ecolab launches EnCompass Environmental Hygiene program to improve patient room hygiene

Ecolab Inc. today announced the launch of its new EnCompass™ Environmental Hygiene program, a comprehensive clinical program that helps hospitals improve patient room hygiene and prevent the spread of infections.

1 Feb 2010

Lakeshore General Hospital restricts patient visits as a result of bacterial outbreak

Lakeshore General Hospital, a West Island HSSC facility, is restricting patient visits in the 4-West medical unit as a result of a bacterial outbreak. Other services provided by this hospital centre will not be affected. This preventive measure will remain in place until January 5.

30 Dec 2009

Malaria nasal vaccine, antimicrobial peptide against MRSA, and safer method to prolong orange juice shelf life

An experiemental nasally administered malaria vaccine prevented parasite transmission from infected mice to mosquitoes and could play an important role in the fight against human malaria. The researchers from Japan report their findings in the December 2009 issue of the journal Infection and Immunity.

19 Dec 2009

bioMerieux announces the upcoming availability of ABxAlert from ICNet International

bioMerieux, a world leader in the field of in vitro diagnostics, announced the upcoming availability of ABxAlert® from ICNet International Ltd., a global clinical informatics company, at the 44th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition.

8 Dec 2009

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Chaperone Technologies, Inc. and MerLion Pharmaceuticals Pte Ltd., both privately-held companies developing new antimicrobial drugs, announced today that they are together evaluating a unique approach for the treatment of resistant and life-threatening bacterial infections.

4 Dec 2009

BD acquires HandyLab for $275 million

BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.

From BD (Becton, Dickinson and Company) 20 Nov 2009

SDC-based hard surface disinfectant is effective against the 2009 H1N1

PURE Bioscience, creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that its SDC-based hard surface disinfectant is effective against the 2009 H1N1 and is included on the list published by the U.S. Environmental Protection Agency (EPA) of antimicrobial products effective against the 2009 H1N1 flu strain based on their effectiveness against other influenza A virus strains.

27 Oct 2009

BD to acquire HandyLab

BD (Becton, Dickinson and Company)announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.

From BD (Becton, Dickinson and Company) 24 Oct 2009

Study on the economic impact of antibiotic overuse and antibiotic-resistant infections

The Alliance for the Prudent Use of Antibiotics (APUA) and Cook County Hospital (currently John H. Stroger, Jr. Hospital of Cook County), today announced the release of an eye-opening study on the economic impact of antibiotic overuse and antibiotic-resistant infections (ARIs) sponsored by an unrestricted educational grant from bioMerieux and the Centers for Disease Control and Prevention (CDC).

19 Oct 2009

TAXIS Pharmaceuticals, Rutgers and UMDNJ to develop and commercialize a novel antimicrobial technology

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections.

14 Oct 2009

Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development

Paratek Pharmaceuticals, Inc. announced today that it has entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement with Novartis for Paratek's lead broad-spectrum antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC) in Phase 3 clinical trials.

8 Oct 2009

Report on the worldwide market for anti-infectives

Drug resistance is a key public health problem and also a problem for makers of branded antibacterial products, according to the findings of a new report. Traditional antibiotics: quinolones, cephalosporins, and penicillins, have seen their market share erode due to loss of effectiveness, while at the same time they are facing heavy generic competition.

3 Oct 2009

E. coli pervasive in stream-water with fecal indicator bacteria

Bacteria commonly used to indicate health risks in recreational waters might not be so reliable after all. Pathogenic E. coli were pervasive in stream-water samples with low concentrations of fecal indicator bacteria.

23 Sep 2009

Biochemists are developing a new system to better understand antibiotic resistance

Rice University biochemists are developing a system of "evolutionary forecasting" to better understand the mechanisms of antibiotic resistance.

22 Sep 2009

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria.

16 Sep 2009

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

16 Sep 2009

Bloodstream infections can be avoided with a daily scrub solution bath

Giving critically ill hospital patients a daily bath with a mild, soapy solution of the same antibacterial agent used by surgeons to "scrub in" before an operation can dramatically cut down, by as much as 73 percent, the number of patients who develop potentially deadly bloodstream infections, according to a new study by patient safety experts at The Johns Hopkins Hospital and five other institutions.

5 Sep 2009

Study reveals safety of ConvaTec's advanced antimicrobial dressing

ConvaTec, a world-leading provider of innovative medical technologies for community and hospital care, today announced new data showing that AQUACEL(R) Ag, the company's advanced antimicrobial dressing, is safe for use in an MRI environment.

25 Aug 2009

Machine designed to reduce infections and cut back on expensive "disposables"

Johns Hopkins experts in applied physics, computer engineering, infectious diseases, emergency medicine, microbiology, pathology and surgery have unveiled a 7-foot-tall, $10,000 shower-cubicle-shaped device that automatically sanitizes in 30 minutes all sorts of hard-to-clean equipment in the highly trafficked hospital emergency department.

30 Jul 2009

Toddler’s mysterious meningitis trumps cancer threat

Brooklynn Spencer's mother Samantha knew something wasn't right. The 8 month old had the flu recently, but it had been four weeks. She should have been better. The Elmira mother of four pushed for blood tests in early October 2007. A few hours later, there was a knock at the door.

21 May 2009